drugset / Trial / NCT00496015

Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A

NCT00496015

Phase 3 Completed 750 enrolled GlaxoSmithKline
Non-randomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this trial is to assess if the rate of febrile reactions following the co-administration of a booster dose of pneumococcal conjugate vaccines with standard infant vaccines is lowered when paracetamol is given prophylactically and to assess the impact of pneumococcal conjugate vaccine on pneumococcal and H. influenzae nasopharyngeal carriage compared to control group receiving meningococcal conjugate vaccine (GSK134612). This protocol posting deals with objectives \& outcome measures of the booster phase. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00370318).

Timeline

Start
2007-07-02
Primary completion
2008-03-25
Completion
2009-02-17

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Acetaminophen Small molecule 125 mg Rectal
Subject GSK1024850A Vaccine Intramuscular
Comparator GSK134612 Vaccine Intramuscular
Background Infanrix hexa Vaccine Intramuscular